The Access Barrier Cause-Effect Canvas

Helping precision medicine advocates and champions visualize the patient experience and barriers patients and other stakeholders face in accessing Precision Medicine solutions.

Identifying access barriers and potential solutions

Understanding the access barriers faced by stakeholders throughout the patient pathway is crucial.

The Access Barrier Cause-Effect Canvas is a foundational framework designed for precision medicine advocates and champions. It helps map the patient pathway for specific conditions or regions, identify access barriers encountered by various stakeholders, and discover potential solutions or best practices to overcome these challenges.

Simple to use

Designed for anyone working to advance access to personalized healthcare—whether you’re a patient advocate of any experience level, a healthcare professional, or an industry member.

Versatile for all focus areas

Applicable to any condition, in any geography, and across the entire patient care pathway.

How to use this tool

Download the canvas

Review

Carefully examine the structure and examples provided.

Plan

Decide how you want to utilize the tool—for which groups, conditions, and geographies.

Tool in action

Discover all adapted resource from the Access Barrier Cause-Effect Canvas

Building on existing good practices

The tool was built through a collaborative approach, drawing from good practice resources from LUNGevity, the IQVIA Institute and National Oncology Alliance – Rare Cancers Australia. It builds on good practice resources and insights shared by a diverse multi-stakeholder group including patient advocates, industry, academics, researchers and external experts.

We thank all our partners for their contribution and inspiration.

The tool was built through a collaborative approach, drawing from good practice resources from:

Meet the people behind this tool

Connect with Us

Want to learn more about this resource? Interested in adapting it to your country or condition?

Fill out this form.

Follow us: